Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The objective of the study is the PK-PD modelling of APO in healthy subjects.

Why It Was Studied

Apomorphine (APO) stimulates growth hormone (GH) release via dopamine D2 receptors (DRD2).

APO concentrations were modelled according to both a bi-compartmental model with zero-order absorption and a bi-compartmental model with first-order absorption.

Who Took Part

According to the abstract, 18 subjects were involved.

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

The subjects were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Apomorphine, Area Under Curve, Dopamine Agonists, Half-Life, Human Growth Hormone and Models, Biological.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (Fundamental & clinical pharmacology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.